Axsome Therapeutics (AXSM) Other financing activities (2022 - 2026)

Axsome Therapeutics has disclosed Other financing activities across 5 years of filings, most recently posting $95000.0 for Q1 2026.

• Other financing activities for Q1 2026 came in at $95000.0, down 75.83% year-over-year; the trailing twelve-month figure through Mar 2026 was $899000.0 (down 25.64% YoY), and the FY2025 annual result was $1.2 million, up 46.69% from the prior year.
• Other financing activities came in at $95000.0 for Q1 2026 at Axsome Therapeutics, up from -$2.4 million in the prior quarter.
• In the past five years, Other financing activities ranged from a high of $12.4 million in Q2 2023 to a low of -$2.4 million in Q4 2025.
• The 5-year median for Other financing activities is $455000.0 (2025), against an average of $2.0 million.
• Peak annual rise in Other financing activities reached 941.22% in 2025, while the deepest fall reached 841.95% in 2025.
• Axsome Therapeutics' Other financing activities stood at $6.5 million in 2022, then slumped by 68.46% to $2.0 million in 2023, then slumped by 83.92% to $329000.0 in 2024, then tumbled by 841.95% to -$2.4 million in 2025, then surged by 103.89% to $95000.0 in 2026.
• The last three Other financing activities figures came in at $95000.0 (Q1 2026), -$2.4 million (Q4 2025), and $2.7 million (Q3 2025), per Business Quant data.